Modified release pellets: one path to optimized drug product
Sponsored by: Recipharm
- Modified Release Technology
- Drug Substances
Date: 3 November
Time: 3PM London/10AM New York
Modified release technology can be used to improve the performance of new chemical entities (NCEs) as well as existing drug substances. There are many advantages of modified release products, including less frequent dosing, improved patient compliance and decreased side effects. For existing products the technology creates new possibilities not only for the patient but also for the pharma company, for example extending exclusivity rights.
There are several well-established modified release technologies that allow for greater control over the rate and/or site of release of drugs, allowing pharma companies to achieve specific clinical objectives that cannot be attained with conventional dosage forms. Coated pellets are extremely useful to achieve a range of different release profiles, however their development can be challenging.
In this webinar, Torkel Gren, Senior Director, Science & Technology Officer and Aaron Small, Vice President Global Development Sales will discuss the advantages and challenges of using coated pellets as a modified release technology and techniques to ensure success.
Register now for this webinar on Modified release pellets: one path to optimized drug product.
Torkel Gren, PhD,
Senior Director, Technology Officer & Strategic Investments
Torkel is Senior Director, Science & Technology Officer at Recipharm AB. He holds degrees in Pharmacy and Business Administration as well a PhD in Pharmaceutics (Uppsala University). He has worked in the pharmaceutical industry since 1988 and has held a number of scientist and manager positions in Europe and the US. He was lead formulator and co-inventor of Detrol OD/Detrusitol SR. Torkel is vice chairman of the board of the Swedish Pharmaceutical Society.
Philippe Gorria, PhD,
Senior Director, Formulation Development
Philippe is Senior Director, Formulation Development at Recipharm. In his role Phillipe is responsible for the development and formulation of oral dosage forms using controlled drug delivery systems with his team. With over 15 years' experience in the pharmaceutical industry, and almost 25 years in life sciences, he has held a number of both scientific and managerial positions within start-ups and pharma companies. He has a degree in physics and a PhD in physical-chemistry from the Bordeaux University in France.
Vice President- Global Development Sales
Aaron Small is Vice President Global Development Sales at Recipharm. He holds a BSBA degree in Marketing and a MBA and has been a part of Recipharm since 2011. During his time in Recipharm he has contributed to business development activities for both development and manufacturing services. In addition Aaron has been a part of brand development and deployment for the North American market.
Key Learning Objectives
- Explore the potential to create new products using pellet technology
- Examine the advantages of using pellets to achieve modified release products
- Understand the challenges of pellet technology and how to overcome development hurdles
- A case study where pellets are used to achieve modified release will also be discussed.
- Analytical services - Manager/Director/Head/VP
- CMC - Manager/Director/Head/VP
- Development - Manager/Director/Head/VP
- Formulation development - Manager/Director/Head/VP
- Pharmaceutical development -Manager/Director/Head/VP
- Chemistry/Medicinal Chemistry -Manager/Director/Head/VP
- Founder and CEO
- Procurement - Manager/Director/Head/VP